Compare Abbott Laboratories (ABT) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs JetBlue Airways Corporation — how do they compare? Abbott Laboratories trades at $95.25 (market cap $166.94B), while JetBlue Airways Corporation trades at $5.63 (market cap $2.13B). The key difference: Abbott Laboratories is far larger — about 78.4× JetBlue Airways Corporation's market cap, and Abbott Laboratories pays a 2.63% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| ABT | JBLU | |
|---|---|---|
Market Cap | $166.94B | $2.13B |
Sector | Health | Industrials |
52-Week High | $136.62 | $6.46 |
52-Week Low | $82.57 | $4.03 |
Enterprise Value | $193.69B | $9.30B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
JetBlue (JBLU) trades at $5.72, down 4.98% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The airline faces fundamental challenges with negative net income margins (-7.78%) and ROE (-33.51%) despite a low P/S ratio of 0.24. Recent strategic shifts include expanding premium Mint service in Fort Lauderdale while reducing New York operations to cut costs.
The outlook remains cautious with Wall Street showing limited conviction (19% buy rating) and a consensus price target of $5.12 below current levels. Key risks include persistent losses, high debt levels (debt-to-asset ratio over 50%), and competitive pressures, though lower fuel costs and travel demand provide some sector support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
